Edding Genor Group Holdings Ltd
Company Profile
Business description
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
Contact
No. 36 Doukou Road
Room 406, Building 1
Hengqin New Area
Guangdong Province
Zhuhai
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,545
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.00 | 57.00 | -0.63% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 24,491.68 | 516.92 | -2.07% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 63,224.35 | 3,611.19 | -5.40% |
| NZX 50 Index | 13,632.12 | 17.34 | 0.13% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,769.60 | 47.20 | -0.54% |
| SSE Composite Index | 3,818.59 | 63.82 | -1.64% |